CA-PRE-SWITCH
Pre-Switch, Inc., the world’s premier supplier of soft switching technology, today introduced Pre-Flex™ Technology, an embedded AI (Artificial Intelligence) controller IC (Integrated Circuit) which effectively eliminates transistor switching losses in hard-switched architectures for virtually any power converter topology. Pre-Flex dramatically reduces cost, size and weight, while increasing efficiency and reliability of power converters in the server, solar, wind, EV, traction and motor drive markets.
Pre-Flex technology learns and adapts “in-system,” on a cycle-by-cycle basis, to reliably force resonant soft-switch across changing loads, input voltages, temperatures and manufacturing tolerances. The technology has proven efficiencies greater than those of five-level topologies at a fraction of the cost and complexity. Pre-Flex also significantly lowers EMI (Electromagnetic interference) and dramatically decreases dV/dt for any switch type. Pre-Flex enables Silicon carbide-like performance for low-cost IGBTs, and allows SiC- and GaN-based topologies to switch up to 20x faster than they do today. Built into the architecture are innovative cycle-by-cycle safety features and communications that were never possible before. Pre-Flex has switched 900V Wolfspeed SiC MOSFETs up to 1MHz, and 650V Infineon IGBTs at over 100 kHz with unprecedented efficiencies. The technology presently scales from 1 KW to above gigawatts.
“We have removed the biggest barrier to advancing the power conversion industry,” said Bruce Renouard, chief executive officer of Pre-Switch, Inc. “Our technology enables simple, reliable and cost-effective forced resonant soft-switching on any topology.”
Pre-Switch is working with development partners interested in leading their respective industries by designing their next-generation power converters with Pre-Flex technology.
“By significantly reducing IGBT switching losses without increasing dV/dt, Pre-Switch is creating a possibility to redefine our VFD motor drives to be smaller and more efficient without being harmful to motor insulation and bearings,” said Adalberto Jose Rossa, Drives R&D manager of WEG Drives & Controls. “We are investigating this technology, and initial test results at double-pulse and at short-circuit conditions have inspired us to test a complete drive with Pre-Switch technology. We look forward to analyzing reliability data of the system under real motor load conditions.”
“The higher switching frequencies enabled by Pre-Switch are able to provide a lower motor current ripple,” said Carlos Afonso Hümmelgen, Drives R&D coordinator from WEG Drives & Controls. “Lower motor current ripple yields reduced motor harmonic losses, and increased motor and system efficiency.”
Pre-Switch will be at PCIM Europe 2018 in Nuremberg, Germany, at booth 6-147 in Hall 6.
About Pre-Switch, Inc.
Pre-Switch, Inc. is a Silicon Valley power architecture company that develops embedded AI technology to solve complex timing problems associated with forced resonance soft-switching in power conversion. The company was founded by industry experts in power semiconductors, power systems, robotics, and artificial intelligence. Pre-Flex technology is patent pending globally. For more information, visit www.pre-switch.com/ .
Pre-Switch®, the Pre-Switch logo and other trademarks or service names are the trademarks of Pre-Switch, Inc. or of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531006141/en/
Contact:
for Pre-Switch, Inc.
Christian Zdebel, 484-788-2384
cz@silversection.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom